GE Healthcare's Pharmaceutical Diagnostics business is investing $80 million to increase manufacturing capacity by 30% at its Active Pharmaceutical Ingredients site in Lindesnes, Norway.
The company said the investment aims to create around 100 new jobs. The investment is part of the company's broader commitment to address future global demand for iodinated contrast media, GE said. The goal is to produce 30 million more doses of contrast media per year by 2025.
The 100-acre Lindesnes site has been operating since 1974 and employs 450 people. Recently, GE Healthcare entered into a multiyear agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine for the contrast media.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
